AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 232 min read$ABBV

FDA approves AbbVie’s Crohn’s drug for home shots; 74% of patients with no prior advanced-treatment failure were in remission at week 12.

FDA approved AbbVie's subcutaneous SKYRIZI for Crohn's disease, allowing home administration. Phase 3 AFFIRM study showed 74% remission in patients without prior advanced therapy failure at week 12. Safety profile consistent with known risks. FDA also updated TB testing guidelines for SKYRIZI. According to AbbVie, this approval provides greater treatment flexibility. SKYRIZI is an IL-23 inhibitor approved for several immune-mediated diseases.

Original reporting
stocktitan.net
Published Oct 23, 2026, 7:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 7:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$ABBV
Bullish
high confidence
Mentioned
$ABBV
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

The approval expands SKYRIZI's addressable market and may accelerate adoption, supporting AbbVie's revenue growth in the gastroenterology franchise.

02

Market read

Regulatory approval is a material catalyst for AbbVie, likely prompting short‑term buying pressure and influencing the broader biotech sector.

03

What to watch

Potential competition from biosimilars and the need for payer acceptance of the new delivery device.

Relevance 7/10Novelty 8/10Timing: immediate market reaction today

Background

AbbVie announced FDA approval of a subcutaneous induction formulation of SKYRIZI for Crohn's disease, adding an on-body injector option.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

FDA approved AbbVie’s subcutaneous SKYRIZI for Crohn's disease, providing a new administration route and expanding the drug's market.

Expected impact

upward pressure as investors price in additional revenue from the subcutaneous indication.

Evidence & confidence

Regulatory approval is a primary catalyst; the drug already has a sizable market and the new route adds convenience, which historically drives sales uplift.

Market effects

Sector

Strengthens the IBD/IBS biotech segment and may raise expectations for other IL‑23 inhibitors.

Regional

U.S. biotech stocks could see modest gains as the approval highlights pipeline potential.

Global

Limited to markets where AbbVie is listed, but may influence global peers developing similar therapies.

Counterpoint

What could challenge this read

If pricing or reimbursement issues arise, the upside could be muted despite approval.

Key entities

  • Company
    AbbVie

    Pharmaceutical company receiving FDA approval for SKYRIZI subcutaneous formulation.

  • Drug
    SKYRIZI (risankizumab)

    IL‑23 inhibitor now approved for subcutaneous induction in Crohn's disease.

Read at source← All news

StoryFDA approves subcutaneous induction regimen of AbbVie’s SKYRIZI for Crohn’s disease

Also covered by

5 outlets

Related articles

OCT 23
$ABBVHigh

Abbvie Announces U.S. Fda Approval of Subcutaneous Induction Regimen for Skyrizi for Adults with Moderately to Severely Active Crohn's Disease

AbbVie's SKYRIZI (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval follows positive Phase 3 trial results, showing significant clinical remission and endoscopic response in patients. SKYRIZI can now be administered at home using an on-body injector, with induction doses at weeks 0, 2, 4, and 8, followed by maintenance dosing every eight weeks.

marketscreener.com2 min
OCT 23
$ABBVHigh

AbbVie (ABBV) Gains FDA Nod for At-Home Skyrizi Induction in Cro

AbbVie (ABBV) received FDA approval for an at-home subcutaneous induction regimen for its drug Skyrizi, allowing adults with moderate to severe Crohn’s disease to start treatment at home. The company offers a 2.34% dividend yield with a high payout ratio of 85% and a 3-year dividend growth rate of 5.2%. AbbVie's GF Value™ suggests the stock is modestly overvalued at $222.72 versus the current price of $286.20.

gurufocus.com3 min
OCT 23
$ABBVHigh

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SK

AbbVie's SKYRIZI (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval is based on positive Phase 3 AFFIRM trial results, showing superior clinical remission and endoscopic response at week 12 compared to placebo, especially in treatment-naïve patients. The subcutaneous form allows for at-home administration using an on-body injector.

gurufocus.com2 min
OCT 23
$ABBVHigh

FDA approves subcutaneous induction regimen for AbbVie’s Skyrizi

AbbVie (ABBV) received FDA approval for a subcutaneous induction regimen of Skyrizi for Crohn's disease. The regimen involves 720 mg doses at weeks 0, 2, 4, and 8, with maintenance doses every 8 weeks. The approval is based on Phase 3 trial results showing 56% clinical remission vs. 30% for placebo. The FDA also updated prescribing info to remove mandatory TB testing. Skyrizi is approved for several autoimmune diseases.

investing.com2 min